ABIVAX Société Anonyme/€ABVX
06:30
10:10
13:45
17:25
21:00
1D1W1MYTD1Y5YMAX
About ABIVAX Société Anonyme
Abivax Société Anonyme is a clinical-stage biotechnology company headquartered in Paris, France, with a research center in Montpellier and a U.S. office in Waltham, Massachusetts. Founded in December 2013, the company focuses on developing therapeutics that modulate the immune response to treat chronic inflammatory diseases. Its lead drug candidate, obefazimod (formerly ABX464), is in Phase 3 clinical trials for moderately to severely active ulcerative colitis and is being prepared for a Phase 2a trial in Crohn's disease. Abivax collaborates closely with the French National Center for Scientific Research (CNRS), the Institut Curie, and the University of Montpellier. In 2015, the company raised €57.7 million in its initial public offering on Euronext Paris, and in October 2023, it raised €232.3 million through an IPO on the Nasdaq Global Market.
Ticker
€ABVX
Sector
Primary listing
PAR
Employees
69
Headquarters
Website
ABVX Metrics
BasicAdvanced
€6.7B
-
-€3.09
0.13
-
Price and volume
Market cap
€6.7B
Beta
0.13
52-week high
€91.00
52-week low
€4.51
Average daily volume
5.7K
Financial strength
Current ratio
0.766
Quick ratio
0.674
Long term debt to equity
-103.281
Total debt to equity
-204.449
Interest coverage (TTM)
-13.11%
Profitability
EBITDA (TTM)
-185.652
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-3,244.03%
Operating margin (TTM)
-3,099.50%
Revenue per employee (TTM)
€90,000
Management effectiveness
Return on assets (TTM)
-57.74%
Return on equity (TTM)
-499.78%
Valuation
Price to revenue (TTM)
948.908
Price to book
-116.22
Price to tangible book (TTM)
-76.54
Price to free cash flow (TTM)
-42.03
Free cash flow yield (TTM)
-2.38%
Free cash flow per share (TTM)
-2.148
Growth
Revenue change (TTM)
-33.90%
Earnings per share change (TTM)
-1.57%
3-year revenue growth (CAGR)
39.30%
10-year revenue growth (CAGR)
28.28%
3-year earnings per share growth (CAGR)
3.18%
10-year earnings per share growth (CAGR)
9.86%
Bulls say / Bears say
The 50 mg once-daily dose of obefazimod achieved a pooled 16.4% placebo-adjusted clinical remission rate at Week 8 (p<0.0001), demonstrating strong Phase 3 efficacy in patients with moderately to severely active ulcerative colitis (BioPharma Dive).
Obefazimod showed a favorable safety profile in the Phase 3 ABTECT induction studies, with no new safety signals reported and only transient headaches as the main adverse event, indicating good tolerability in various patient groups (Investors.com).
Abivax completed a $747.5 million public offering in July 2025, raising about $700.3 million in net proceeds to support Phase 3 development of obefazimod and upcoming Phase 2 trials in Crohn’s disease, extending its funding through late 2027 (BioSpace).
Data summarised monthly by Lightyear AI. Last updated on 8 Nov 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for ABIVAX Société Anonyme stock?
ABIVAX Société Anonyme (ABVX) has a market cap of €6.7B as of November 10, 2025.
What is the P/E ratio for ABIVAX Société Anonyme stock?
The price to earnings (P/E) ratio for ABIVAX Société Anonyme (ABVX) stock is 0 as of November 10, 2025.
Does ABIVAX Société Anonyme stock pay dividends?
No, ABIVAX Société Anonyme (ABVX) stock does not pay dividends to its shareholders as of November 10, 2025.
When is the next ABIVAX Société Anonyme dividend payment date?
ABIVAX Société Anonyme (ABVX) stock does not pay dividends to its shareholders.
What is the beta indicator for ABIVAX Société Anonyme?
ABIVAX Société Anonyme (ABVX) has a beta rating of 0.13. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.